Xanomeline oxalate Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

371.45

DMSO: 50mg/mL (134.61mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C16H25N3O5S

CN1CCC=C(C2=NSN=C2OCCCCCC)C1.O=C(O)C(O)=O

141064-23-5

muscarinic receptor

Xanomeline increased striatal levels of dopamine metabolites, presumably by acting at M1 heteroreceptors on dopamine neurons to increase dopamine release. In contrast, xanomeline had only a relatively small effect on acetylcholine levels in brain, indicating that it is devoid of actions at muscarinic autoreceptors. The effects of xanomeline on ex vivo binding and DOPAC levels lasted for about 3 hr and were evident after oral administration. An analog of xanomeline with similar in vivo effects did not inhibit acetylcholinesterase or choline acetyltransferase and inhibited choline uptake only at concentrations much higher than those required to inhibit binding[1].